Gamma-Aminobutyric Acid Type B Receptor Subunit 1 (Gabbr1) Antibody (FITC)

Product specifications

Primary Antibodies

Gamma-Aminobutyric Acid Type B Receptor Subunit 1 (Gabbr1)

Mouse

Human, Mouse, Rat

WB: 1/1000. Optimal dilutions/concentrations should be determined by the end user.

Monoclonal

FITC

IgG1

Purified by Protein G.

100 µg

WB, IF/ICC

PBS, pH 7.4, 50% glycerol, 0.09% sodium azide.

Shipped within 5-12 working days.

Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.

No

Q9Z0U4

81657

NP_112290.2

GABBR1,GPRC3A,GABA-B receptor 1,GABABR1,gamma-aminobutyric acid (GABA) B receptor 1,gamma-aminobutyric acid (GABA) B receptor

Antibody anti-GABBR1

RUO

Concentration: 1 mg/ml - 

Descripción

GABBR1 is a subunit of the metabotropic GABA-B receptor, a G protein-coupled receptor that mediates the inhibitory effects of gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the central nervous system. GABBR1 forms an obligate heterodimer with GABBR2 to function effectively, and it couples to Gi/o proteins, inhibiting adenylate cyclase activity and reducing intracellular cAMP levels. This inhibition leads to decreased neurotransmitter release, regulation of synaptic transmission, and neuronal excitability. GABBR1 is widely expressed in the brain, particularly in regions involved in cognition, pain perception, and behavior. Dysregulation of GABBR1 is associated with neurological and psychiatric disorders, including epilepsy, anxiety, depression, and addiction. GABA-B receptors, including GABBR1, are targets for drugs like baclofen, which is used to treat spasticity and certain substance abuse disorders. Beyond the CNS, GABBR1 plays roles in insulin secretion and gastrointestinal motility. Its essential function in inhibitory neurotransmission makes GABBR1 a key target for therapeutic development in neurological and metabolic disorders.

Related Products

GABBR1 antibody

Component of a heterodimeric G-protein coupled receptor for GABA, formed by GABBR1 and GABBR2. Within the heterodimeric GABA receptor, only GABBR1 seems to bind agonists, while GABBR2 mediates coupling to G proteins. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins(G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase, stimulates phospholipase A2, activates potassium channels, inactivates voltage-dependent calcium-channels and modulates inositol phospholipid hydrolysis. Calcium is required for high affinity binding to GABA. Plays a critical role in the fine-tuning of inhibitory synaptic transmission. Pre-synaptic GABA receptor inhibits neurotransmitter release by down-regulating high-voltage activated calcium channels, whereas postsynaptic GABA receptor decreases neuronal excitability by activating a prominent inwardly rectifying potassium(Kir) conductance that underlies the late inhibitory postsynaptic potentials. Not only implicated in synaptic inhibition but also in hippocampal long-term potentiation, slow wave sleep, muscle relaxation and antinociception. Activated by(-)-baclofen, cgp27492 and blocked by phaclofen. Isoform 1E may regulate the formation of functional GABBR1/GABBR2 heterodimers by competing for GABBR2 binding. This could explain the observation that certain small molecule ligands exhibit differential affinity for central versus peripheral sites.

Ver Producto

Gamma-Aminobutyric Acid Type B Receptor Subunit 1 (GABBR1) Antibody

Rabbit polyclonal antibody against GABA-B Receptor protein. Immunogen region is C-terminal.

Ver Producto

Gamma-Aminobutyric Acid B Receptor 1 (gABBR1) Antibody

gABBR1 Antibody is a Rabbit Polyclonal antibody against gABBR1.

Ver Producto